Drug intelligence / Profile preview

miRNAI

Development stage: Preclinical
Lead developer: Pharmahungary Group
Modality: RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous

Overview

miRNAI is an AI-driven bioinformatics and therapeutic discovery platform developed by Pharmahungary Group. The platform leverages artificial intelligence to identify and optimize microRNA (miRNA) and miRNA-combination therapeutics. Currently in the preclinical discovery stage, miRNAI is designed to be disease-agnostic, enabling the identification of novel miRNA-based interventions for a wide range of medical conditions by analyzing complex regulatory networks. The platform aims to streamline the discovery of miRNA therapeutics, which function by modulating gene expression at the post-transcriptional level.

Beyond the preview

Go deeper on miRNAI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miRNAI.

Explore the full profile